PROSCA/BLADDR 2023 | The future of non-muscular invasive bladder cancer management

Felix Guerrero-Ramos, MD, PhD, Hospital Universitario 12 de Octubre in Madrid, Spain, discusses the evolving landscape of non-muscle invasive bladder cancer (NMIBC) and the potential inclusion of systemic therapies. Traditionally managed by urologists, NMIBC treatment may see changes as systemic therapies show efficacy and gain regulatory approval. Dr Guerrero-Ramos emphasizes the need for well-trained doctors, especially urologists, to manage the toxicities associated with these therapies. In a multidisciplinary approach, including medical oncologists, urologists, pathologists, and other specialists, decisions about patient treatment will be collaboratively made. Dr Guerrero-Ramos envisions a future where the management of NMIBC involves a broader spectrum of expertise within multidisciplinary teams, ensuring better outcomes for patients. This interview took place at the Global Congress on Prostate and Bladder Cancer (PROSCA/BLADDR) 2023 in Malaga, Spain.

These works are owned by Magdalen Medical Publishing, protected by global copyright laws. All rights are reserved.